| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | MRK | Common Stock | 100 | Jun 30, 2021 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRK | Phantom Stock | Award | $16.3K | +209 | +3.28% | $77.77 | 6.57K | Jun 30, 2021 | Common Stock | 209 | Direct | F1, F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | 1-for-1 |
| F2 | Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. |
| F3 | Holdings include shares acquired in dividend reinvestment transactions. |
| F4 | Holdings reflect the adjustment that occurred as of June 2, 2021 in connection with the Organon spin-off as described in the registration statement on Form 10 filed with the SEC for Organon & Co. (the "Form 10"). As reported in the Form 10, each Merck phantom share outstanding under the Merck Deferred Compensation Plan as of immediately prior to the distribution date was converted on the distribution date into an adjusted Merck phantom share with the number of units represented by such award adjusted to preserve the aggregate value of the original Merck phantom shares as measured before and immediately after the distribution. |